MedTrace Logo

Ticagrelol Versus Aspirin in Ischemic Stroke

NCT03884530 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2021-09-02

No results posted yet for this study

Summary

There is a debate whether ticagrelor is superior to aspirin in treating patients with ischemic stroke or not, most of the studies examine the effect of both drugs within 24 hours of acute stroke some find that there is no difference between ticagrelor and aspirin, others find that ticagrelor is superior to aspirin.

At this study the investigators aim at evaluating the role of loading ticagrelor received within 9 hours of acute ischemic stroke in improving neurological outcome of stroke. And evaluating the risk of hemorrhagic and non- hemorrhagic complications associated with the use of ticagrelor180 ml oral loading dose within 9 hours acute ischemic stroke

Conditions

Interventions

DRUG

Ticagrelor (Brilique) 90

Drug name Brilique 90 ml Drug form tablet

DRUG

Aspirin 75mg

Drug name Aspirin 75 ml Drug form tablet

Sponsors & Collaborators

  • Ain Shams University

    collaborator OTHER

  • Kafrelsheikh University

    lead OTHER

Principal Investigators

  • Hani Mohamed M Aref, MD · neuropsychiatry department Ain shams faculty of medicine

  • Hala M Elkhawas, MD · neuropsychiatry department Ain shams faculty of medicine

  • Ahmed I Elbassiouny, MD · neuropsychiatry department Ain shams faculty of medicine

  • Tamer M Roushdy, MD · neuropsychiatry department Ain shams faculty of medicine

  • Hossam S Mohammed, MD · neuropsychiatry department Ain shams faculty of medicine

  • Mohamed Zeinhom M Gomaa, M.Sc. · neuropsychiatry department Kafrelsheikh faculty of medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03884530 on ClinicalTrials.gov